{"id":"monotherapy-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1138","moleculeType":"Small molecule","molecularWeight":"409.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezetimibe selectively binds to NPC1L1, a sterol transporter located on the brush border of the small intestine, preventing the uptake of dietary and biliary cholesterol. This reduces intestinal cholesterol absorption and leads to decreased plasma LDL cholesterol levels. The mechanism is distinct from statins, making ezetimibe useful as monotherapy or in combination with other lipid-lowering agents.","oneSentence":"Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:59.310Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (monotherapy)"},{"name":"Primary hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT07219602","phase":"PHASE3","title":"A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome","status":"RECRUITING","sponsor":"NewAmsterdam Pharma","startDate":"2025-12-11","conditions":"Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)","enrollment":300},{"nctId":"NCT07445542","phase":"","title":"Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2021-12-18","conditions":"Hypercholesterolemia","enrollment":6927},{"nctId":"NCT07442630","phase":"PHASE4","title":"Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides","status":"ACTIVE_NOT_RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2023-08-21","conditions":"Hypercholesterolemia","enrollment":88},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT05782777","phase":"NA","title":"Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-04-07","conditions":"Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation","enrollment":4310},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT04626973","phase":"NA","title":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2021-01-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":3048},{"nctId":"NCT05763875","phase":"PHASE3","title":"Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-15","conditions":"Hypercholesterolemia","enrollment":350},{"nctId":"NCT06005597","phase":"PHASE3","title":"Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-03-01","conditions":"Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":407},{"nctId":"NCT06767345","phase":"PHASE4","title":"Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-05-12","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery, Plaque, Atherosclerotic","enrollment":408},{"nctId":"NCT07083206","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe","status":"RECRUITING","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2025-07-29","conditions":"Hypercholesterolemia, Dyslipidemias","enrollment":4500},{"nctId":"NCT06722521","phase":"PHASE4","title":"GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-09","conditions":"Primary Prevention, Vascular Calcification","enrollment":7435},{"nctId":"NCT06789432","phase":"PHASE4","title":"Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population","status":"RECRUITING","sponsor":"Dr. Md. Alimur Reza","startDate":"2025-02-01","conditions":"Hyperlipidemia (E.G., Hypercholesterolemia)","enrollment":500},{"nctId":"NCT03169985","phase":"PHASE4","title":"Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2017-07-12","conditions":"Coronary Artery Disease","enrollment":280},{"nctId":"NCT06186037","phase":"PHASE4","title":"Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Saint Vincent's Hospital, Korea","startDate":"2024-02-01","conditions":"Coronary Artery Disease, Dyslipidemias, Primary Prevention","enrollment":6356},{"nctId":"NCT06231966","phase":"NA","title":"Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-04-22","conditions":"Peripheral Artery Disease, Polyvascular Disease","enrollment":2462},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":"ASCVD, Diabetes, Statin","enrollment":2000},{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT06293417","phase":"NA","title":"To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-03-01","conditions":"T2DM (Type 2 Diabetes Mellitus), Dyslipidemias","enrollment":3958},{"nctId":"NCT04701242","phase":"NA","title":"Ezetimibe Utilization Early After Acute Myocardial Infarction, \"EzAMI Trial\"","status":"RECRUITING","sponsor":"Cairo University","startDate":"2021-03-24","conditions":"Acute Myocardial Infarction, Dyslipidemias","enrollment":500},{"nctId":"NCT00092560","phase":"PHASE3","title":"Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Hypercholesterolemia, Hypertriglyceridemia","enrollment":587},{"nctId":"NCT00551876","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":214},{"nctId":"NCT00650663","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":247},{"nctId":"NCT00092573","phase":"PHASE3","title":"Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04","conditions":"Hypercholesterolemia, Hypertriglyceridemia","enrollment":576},{"nctId":"NCT05266586","phase":"PHASE2","title":"Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2022-03-09","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":119},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT00871351","phase":"PHASE4","title":"Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-02-01","conditions":"Primary Hypercholesterolemia","enrollment":125},{"nctId":"NCT00867165","phase":"PHASE3","title":"Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-05-21","conditions":"Primary Hypercholesterolemia","enrollment":138},{"nctId":"NCT02460159","phase":"PHASE3","title":"A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2015-06-23","conditions":"Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia","enrollment":135},{"nctId":"NCT02748057","phase":"PHASE3","title":"A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-18","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":135},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT04770389","phase":"PHASE2","title":"Randomized Study of Obicetrapib in Combination With Ezetimibe","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2021-02-23","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":112},{"nctId":"NCT05884502","phase":"PHASE4","title":"A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2022-09-01","conditions":"Dyslipidemias, Stroke, Acute Ischemic","enrollment":330},{"nctId":"NCT05765370","phase":"NA","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-03-24","conditions":"Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol","enrollment":4200},{"nctId":"NCT04895098","phase":"","title":"Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD","status":"COMPLETED","sponsor":"Akrikhin","startDate":"2021-06-23","conditions":"Lipid Metabolism Disorders, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT01763827","phase":"PHASE3","title":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-21","conditions":"Hyperlipidemia","enrollment":615},{"nctId":"NCT00652444","phase":"PHASE4","title":"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT00705211","phase":"","title":"A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia","enrollment":1794},{"nctId":"NCT00704444","phase":"","title":"A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-06","conditions":"Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia","enrollment":11332},{"nctId":"NCT00724477","phase":"","title":"Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10","conditions":"Primary Hypercholesterolemia","enrollment":1663},{"nctId":"NCT00129402","phase":"PHASE3","title":"Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Hypercholesterolemia","enrollment":248},{"nctId":"NCT04584736","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-06-11","conditions":"Primary Hypercholesterolemia","enrollment":283},{"nctId":"NCT03434613","phase":"PHASE4","title":"Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2018-05-14","conditions":"Nonalcoholic Fatty Liver Disease, Dyslipidemias","enrollment":64},{"nctId":"NCT04829149","phase":"","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-06-14","conditions":"Dyslipidemias","enrollment":5717},{"nctId":"NCT04433533","phase":"PHASE4","title":"Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-01-06","conditions":"Left Ventricular Diastolic Dysfunction, Hyperlipidemias","enrollment":200},{"nctId":"NCT03597412","phase":"PHASE4","title":"Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-17","conditions":"Atherosclerotic Cardiovascular Disease, Type 2 Diabetes Mellitus","enrollment":236},{"nctId":"NCT03217409","phase":"PHASE4","title":"A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-08-10","conditions":"Diabetes Mellitus and Hypercholesterolemia","enrollment":85},{"nctId":"NCT03446261","phase":"PHASE4","title":"Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-02-23","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":140},{"nctId":"NCT03044665","phase":"NA","title":"RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-03-15","conditions":"Cardiovascular Diseases, Cerebrovascular Disease, Peripheral Atherosclerotic Disease","enrollment":3780},{"nctId":"NCT03204799","phase":"","title":"Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-12-17","conditions":"Type 2 Diabetes Mellitus, Dyslipidemias","enrollment":150},{"nctId":"NCT02749994","phase":"PHASE3","title":"A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-04","conditions":"Hypercholesterolemia","enrollment":396},{"nctId":"NCT03288038","phase":"PHASE3","title":"The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2014-10-13","conditions":"Hypercholesterolemia","enrollment":382},{"nctId":"NCT00120289","phase":"PHASE3","title":"Niacin Plus Statin to Prevent Vascular Events","status":"TERMINATED","sponsor":"Axio Research. LLC","startDate":"2005-09","conditions":"Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident","enrollment":3414},{"nctId":"NCT02451098","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-391","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-03","conditions":"Hyperlipidemia","enrollment":385},{"nctId":"NCT02445352","phase":"PHASE3","title":"Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2014-07","conditions":"Primary Hypercholesterolemia","enrollment":379},{"nctId":"NCT01043380","phase":"PHASE4","title":"Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2010-01","conditions":"Hypercholesterolemia, Coronary Artery Disease","enrollment":245},{"nctId":"NCT00926055","phase":"NA","title":"Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)","status":"WITHDRAWN","sponsor":"Korea University","startDate":"2011-09","conditions":"Atherosclerosis","enrollment":""},{"nctId":"NCT02251847","phase":"PHASE3","title":"The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2014-07","conditions":"Hypercholesterolemia","enrollment":400},{"nctId":"NCT00405067","phase":"PHASE2","title":"The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-05","conditions":"Hypercholesterolemia","enrollment":60},{"nctId":"NCT00843661","phase":"PHASE4","title":"Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients","status":"UNKNOWN","sponsor":"Ospedale di Circolo - Fondazione Macchi","startDate":"2009-03","conditions":"HIV, Hyperlipidemia, HIV Infections","enrollment":60},{"nctId":"NCT00474123","phase":"NA","title":"Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2006-01","conditions":"Stable Angina","enrollment":78},{"nctId":"NCT01103648","phase":"NA","title":"Effect of Simvastatin and Ezetimibe on Lipid and Inflammation","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2005-06","conditions":"Prediabetes, Hypercholesterolemia, Inflammation","enrollment":50},{"nctId":"NCT00461968","phase":"NA","title":"Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-02","conditions":"Cholesterol, LDL","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":780,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Monotherapy ezetimibe","genericName":"Monotherapy ezetimibe","companyName":"NewAmsterdam Pharma","companyId":"newamsterdam-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezetimibe inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter. Used for Hypercholesterolemia (monotherapy), Primary hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}